➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

McKinsey
McKesson
Dow
Johnson and Johnson
Merck
Medtronic

Last Updated: October 18, 2021

DrugPatentWatch Database Preview

Patent: 8,604,014

➤ Get the DrugPatentWatch Daily Briefing

« Back to Dashboard

Summary for Patent: 8,604,014
Title:Combinations of phosphoinositide 3-kinase inhibitor compounds chemotherapeutic agents, and methods of use
Abstract: Combinations of PI3K inhibitor compounds having Formulas I and II and chemotherapeutic agents, including stereoisomers, geometric isomers, tautomers, metabolites and pharmaceutically acceptable salts thereof, are useful for treating hyperproliferative disorders such as cancer. Methods of using such combinations for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed. ##STR00001##
Inventor(s): Belvin; Marcia (South San Francisco, CA), Friedman; Lori (South San Francisco, CA), Hoeflich; Klaus (South San Francisco, CA), Sampath; Deepak (South San Francisco, CA), Vijapurkar; Ulka (South San Francisco, CA), Wallin; Jeffrey (South San Francisco, CA), Johnson; Leisa (South San Francisco, CA), Singh; Mallika (South San Francisco, CA), Patel; Sonal (Basel, GB)
Assignee: Genentech, Inc. (South San Francisco, CA) F. Hoffmann-La Roche AG (Basel, CH)
Application Number:13/109,670
Patent Claims:see list of patent claims

Details for Patent 8,604,014

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Genentech Inc HERCEPTIN HYLECTA trastuzumab; hyaluronidase-oysk INJECTABLE;SUBCUTANEOUS 761106 2019-02-28 ⤷  Free Forever Trial Genentech, Inc. (South San Francisco, CA) F. Hoffmann-La Roche AG (Basel, CH) 2039-02-26 RX search
Genentech PERJETA pertuzumab VIAL; SINGLE-USE 125409 2012-06-08 ⤷  Free Forever Trial Genentech, Inc. (South San Francisco, CA) F. Hoffmann-La Roche AG (Basel, CH) 2039-02-26 RX search
Genentech AVASTIN bevacizumab VIAL; INTRAVENOUS 125085 2004-02-26 ⤷  Free Forever Trial Genentech, Inc. (South San Francisco, CA) F. Hoffmann-La Roche AG (Basel, CH) 2039-02-26 RX Orphan search
Genentech HERCEPTIN trastuzumab VIAL; INTRAVENOUS 103792 1998-09-25 ⤷  Free Forever Trial Genentech, Inc. (South San Francisco, CA) F. Hoffmann-La Roche AG (Basel, CH) 2039-02-26 RX Orphan search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

International Patent Family for US Patent 8,604,014

Country Patent Number Estimated Expiration
South Africa 201002475 ⤷  Free Forever Trial
World Intellectual Property Organization (WIPO) 2009036082 ⤷  Free Forever Trial
United States of America 2009098135 ⤷  Free Forever Trial
United States of America 2011223619 ⤷  Free Forever Trial
United States of America 2013345217 ⤷  Free Forever Trial
>Country >Patent Number >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Dow
Medtronic
Harvard Business School
AstraZeneca
Mallinckrodt
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.